Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, With EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)

Trial Profile

A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, With EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2019

At a glance

  • Drugs Poziotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms POZITIVE20-1; ZENITH20
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 02 Jan 2019 According to a Spectrum Pharmaceuticals media release, the company has completed enrollment (n=87) in cohort 1 (for previously treated Non-Small Cell Lung Cancer (NSCLC) patients with EGFR exon 20 insertion mutations) of this study.
    • 19 Dec 2018 According to a Spectrum Pharmaceuticals media release, the company will continue to work with the FDA to achieve the fastest route to approval of poziotinib based on the ZENITH20 study.
    • 19 Dec 2018 According to a Spectrum Pharmaceuticals media release, the company expect to complete enrollment in the 87-patient cohort of this study, in the first quarter of 2019, and announce topline data in the second half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top